ciclopirox has been researched along with Granulocytic Leukemia in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Song, S | 1 |
| Christova, T | 1 |
| Perusini, S | 1 |
| Alizadeh, S | 1 |
| Bao, RY | 1 |
| Miller, BW | 1 |
| Hurren, R | 1 |
| Jitkova, Y | 1 |
| Gronda, M | 1 |
| Isaac, M | 1 |
| Joseph, B | 1 |
| Subramaniam, R | 1 |
| Aman, A | 1 |
| Chau, A | 1 |
| Hogge, DE | 1 |
| Weir, SJ | 1 |
| Kasper, J | 1 |
| Schimmer, AD | 1 |
| Al-awar, R | 1 |
| Wrana, JL | 1 |
| Attisano, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 1 Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy[NCT00990587] | Phase 1 | 20 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for ciclopirox and Granulocytic Leukemia
| Article | Year |
|---|---|
Wnt inhibitor screen reveals iron dependence of β-catenin signaling in cancers.
Topics: Acute Disease; Administration, Oral; Benzoates; beta Catenin; Cell Line, Tumor; Cell Proliferation; | 2011 |